Dr. McGregor on New Combinations With Immunotherapy in RCC – OncLive
|
Dr. McGregor on New Combinations With Immunotherapy in RCC
OncLive In addition to the 2 recent phase III trials, CheckMate-214 and IMmotion151, there are emerging combinations with immunotherapy showing promise in RCC. There are currently clinical trials of immunotherapy agents in combination with tyrosine kinase … |
